PubMed=7154478; DOI=10.5980/jpnjurol1928.73.8_1019
Naito K., Hisazumi H., Kanokogi M., Katoh M., Nakazima K., Tsukahara K., Kobayashi T., Kuroda K., Matsubara F.
Establishment of cell lines (KH-39, KN-41, and KW-103) from human kidney and bladder cancer and their characteristics.
Nihon Hinyokika Gakkai Zasshi 73:1019-1031(1982)

PubMed=8621251; DOI=10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0
Tomita Y., Bilim V., Kawasaki T., Takahashi K., Okan I., Magnusson K.P., Wiman K.G.
Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
Int. J. Cancer 66:322-325(1996)

PubMed=10723130; DOI=10.1038/sj.onc.1203449
Alimov A., Kost-Alimova M., Liu J., Li C.-D., Bergerheim U.S.R., Imreh S., Klein G., Zabarovsky E.R.
Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma.
Oncogene 19:1392-1399(2000)

PubMed=10929426; DOI=10.1007/s002400000103
Shintaku I., Kawagoe N., Yutani S., Hoshi S., Orikasa S., Yoshizumi O., Itoh K.
Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Urol. Res. 28:178-184(2000)

PubMed=27993170; DOI=10.1186/s12943-016-0565-8; PMCID=PMC5168717
Brodaczewska K.K., Szczylik C., Fiedorowicz M., Porta C., Czarnecka A.M.
Choosing the right cell line for renal cell cancer research.
Mol. Cancer 15:83.1-83.15(2016)